市场调查报告书
商品编码
1373714
伴侣动物诊断服务全球市场规模、份额、产业趋势分析报告:2023-2030 年按类型、动物类型、测试类别、地区分類的展望与预测Global Companion Animal Diagnostic Services Market Size, Share & Industry Trends Analysis Report By Type (Point-of-Care and Laboratory-based), By Animal Type, By Testing Category, By Regional Outlook and Forecast, 2023 - 2030 |
到 2030 年,伴侣动物诊断服务市场规模预计将达到 104 亿美元,预测期内年复合成长率为 7.4%。
根据 KBV Cardinal 矩阵中发布的分析,Thermo Fisher Scientific Inc. 是市场上的领跑者。 Zoetis, Inc.、Fujifilm Holdings Corporation 和 IDEXX Laboratories, Inc. 等公司是市场上的主要创新者。 2022年12月,FUJIFILM Holdings收购了Inspirata, Inc.,将病理影像和资料整合到医疗机构的电子健康记录系统中。此外,此次收购有助于简化肿瘤患者的定向治疗。
市场成长要素
诊断技术的进步
数位放射线照相、超音波、基因检测和 PCR 检测等诊断技术的进步正在提高宠物诊断服务的准确性和范围。数位X 光技术已在很大程度上取代了传统的基于胶片的 X 光摄影。现在可以实现更清晰、更快速的成像,减少动物和工作人员的辐射暴露,并且现在可以轻鬆地与专家共用影像以进行远端咨询。超音波技术的进步也使得以高解析度和细节对软组织和器官进行成像成为可能。 电脑断层扫描和 MRI 扫描提供极其清晰的3D影像,可以帮助诊断神经系统疾病、肿瘤和肌肉骨骼损伤等复杂疾病。诊断技术的这些进步正在提高伴侣动物的护理质量,并扩大兽医医院提供的服务范围。随着技术的发展,诊断能力预计将变得更加复杂,有助于市场的进一步改善。
宠物健康意识不断增强
宠物饲主越来越意识到预防性动物保健和早期发现疾病的重要性。这种意识是寻求宠物诊断服务的驱动力。了解定期检查和疫苗接种重要性的饲主更有可能安排定期去看兽医。这些访问通常包括诊断测试作为体检的一部分。知识渊博的饲主知道,及早发现疾病可以为宠物带来更有效的治疗和更好的结果。这些饲主更有可能要求对常见健康问题进行诊断测试和筛检。此类方法通常包括诊断测试以指南治疗计划。提高宠物健康意识将有利于市场并提高宠物的寿命和福祉。随着人们意识的不断增强,对诊断服务的需求可能会保持强劲,并进一步推动市场进步。
市场抑制因素
诊断服务费用高
对于一些宠物主人来说,某些诊断测试和程序的费用可能令人望而却步,尤其是那些经济能力较差的饲主饲主。这可能会导致延迟接受必要的兽医护理和诊断。高昂的诊断费用阻碍了饲主投资于定期检查和筛检等预防性护理。结果,错过了早期疾病发现和早期疗育的机会。在农村地区和兽医服务有限的地区,诊断费用可能是宠物医疗保健的主要障碍。宠物饲主必须远距才能获得廉价的服务。因此,诊断服务的高成本对市场构成重大挑战。
按类型分類的展望
按类型划分,服务市场分为现场护理(POC)类型和实验室类型。 2022 年,即时护理 (POC) 领域占据市场最大的销售份额。 POC 领域与远端医疗平台相连,让兽医可以远端咨询宠物饲主,同时使用 POC 诊断评估动物的健康状况。 POC 诊断有助于通用感染疾病监测,并透过快速识别伴侣动物中的潜在病例,为公共卫生配合措施做出贡献。 POC 产业的成长是由于伴侣动物医疗保健领域对方便、快速的现场诊断解决方案的需求不断增长而推动的。
动物物种展望
根据动物类型,市场分为狗、猫、马等。 Cat 细分市场 2022 年在市场中取得了显着的收益占有率。猫的寿命越来越长,老年猫的数量也在增加。这个年龄层需要更频繁的诊断评估,以管理与老龄化相关的健康问题,如肾臟病和关节炎。肠道蠕虫和心臟病等寄生虫的诊断测试对于猫的健康至关重要。随着猫咪数量的增加,对预防性诊断服务的需求也增加。
测试类别的展望
依测试类别,市场分为临床化学、微生物学、寄生虫学、组织病理学、细胞病理学、血液学、免疫学/血清学、诊断影像、分子诊断等。 2022年,临床化学领域占据市场最高收益占有率。临床化学测试通常用于评估伴侣动物的整体健康状况和福祉。临床化学测试为兽医提供基线资料,以监测动物随时间的健康状况。临床化学测试可以检测伴侣动物是否有各种疾病和健康状况。
区域展望
按地区划分,对北美、欧洲、亚太地区和拉丁美洲地区市场进行了分析。 2022 年,北美地区的收益占有率最高,并引领市场。北美是世界上最大的市场之一。由于宠物数量的增加、宠物健康意识的提高、诊断技术的进步以及对宠物预防性保健的日益重视,市场持续成长。北美各地的兽医医院和诊所提供各种诊断服务,包括血液检查、尿液检查、超音波检查、超音波检查和内视镜检查。这些设施为伴侣动物提供全面的照顾。在宠物饲养趋势、先进的医疗保健实践以及对宠物健康和福祉的高度关注的推动下,北美拥有强劲增长的市场。该地区处于兽医诊断创新和实施的前沿。
The Global Companion Animal Diagnostic Services Market size is expected to reach $10.4 billion by 2030, rising at a market growth of 7.4% CAGR during the forecast period.
Cytopathology is performed in real-time during procedures. This immediate feedback aids veterinarians in making on-the-spot decisions about patient care. Thus, the cytopathology segment garnered $342.6 million revenue in the market in 2022. Cytopathology provides rapid results, often within minutes to hours, allowing veterinarians to diagnose and initiate treatment for companion animals quickly. This is particularly valuable in emergency cases and when prompt decisions are essential.
The major strategies followed by the market participants are Acquisitions as the key developmental strategy to keep pace with the changing demands of end users. For instance, In June, 2023, Mars, Inc. completed the acquisition of Heska Corporation. With this acquisition, Mars would achieve wider coverage across diagnostics and technology, better R&D and access to pet healthcare solutions. Additionally, In September, 2022, Zoetis Inc. completed the acquisition of Jurox Pty Limited, an Australian veterinary pharmaceutical manufacturer. Through this acquisition, Zoetis achieved greater worldwide expansion and the manufacture of an anaesthetic product for companion animals called Alfaxan.
Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific Inc. is the forerunner in the Market. Companies such as Zoetis, Inc., Fujifilm Holdings Corporation, IDEXX Laboratories, Inc. are some of the key innovators in Market. In December, 2022, Fujifilm Holdings Corporation acquired Inspirata, Inc., to merge pathology images and data into the electronic health record system of the healthcare organizations. Additionally, the acquisition helped to simplify care designated for oncology patients.
Market Growth Factors
Advancements in diagnostic technologies
Ongoing advancements in diagnostic technologies, such as digital radiography, ultrasound, genetic testing, and PCR assays, have improved the accuracy and range of pet diagnostic services. Digital X-ray technology has largely replaced traditional film-based radiography. It provides clearer and faster imaging, reduces radiation exposure for animals and staff, and allows for easy sharing of images with specialists for remote consultation. Ultrasound technology has advanced, offering higher resolution and better detail for imaging soft tissues and organs. CT and MRI scans provide three-dimensional images with exceptional clarity, aiding in diagnosing complex conditions such as neurological disorders, tumors, and musculoskeletal injuries. These advancements in diagnostic technologies have enhanced the quality of care for companion animals and expanded the range of services that veterinary clinics offer. As technology evolves, diagnostic capabilities will likely become even more advanced, contributing to further improvements in market.
Rising awareness of pet health
Pet owners are becoming increasingly conscious of the significance of preventive care and early disease detection in their animals. This awareness drives them to seek diagnostic services for their pets. Pet owners who know the importance of regular checkups and vaccinations are more likely to schedule routine visits to veterinary clinics. These visits often include diagnostic tests as part of the wellness examination. Knowledgeable pet owners understand that early detection of diseases can lead to more effective treatments and better outcomes for their pets. They are more likely to request diagnostic tests and screenings for common health issues. These approaches often involve diagnostic tests to guide treatment plans. The rising awareness of pet health benefits the market and improves pet longevity and well-being. As this awareness grows, the demand for diagnostic services will likely remain strong, further driving advancements in market.
Market Restraining Factors
High cost of diagnostic services
The cost of certain diagnostic tests and procedures is prohibitive for some pet owners, especially those with limited financial resources. This can lead to delays in seeking necessary veterinary care and diagnostics. High diagnostic costs discourage pet owners from investing in preventive care, including regular checkups and screenings. This can result in missed opportunities for early disease detection and intervention. In rural or underserved areas, where veterinary services are less abundant, the cost of diagnostics can be a significant barrier to pet healthcare. Pet owners need to travel long distances to access affordable services. Therefore, the high costs of diagnostic services pose a significant challenge to the market.
Type Outlook
Based on type, the services market is classified into point-of-care (POC) and laboratory-based. In 2022, the point-of-care (POC) segment witnessed the largest revenue share in the market. The POC segment aligns with telemedicine platforms, allowing veterinarians to consult remotely with pet owners while using POC diagnostics to assess an animal's health condition. POC diagnostics aid in surveilling zoonotic diseases by quickly identifying potential cases in companion animals, thus contributing to public health efforts. The growth of the POC segment is driven by the increasing demand for convenient, rapid, on-site diagnostic solutions in companion animal healthcare.
Animal Type Outlook
On the basis of animal type, the market is divided into dogs, cats, horses, and others. The cats segment recorded a remarkable revenue share in the market in 2022. Cats are living longer, and the senior cat population is growing. This age group requires more frequent diagnostic assessments to manage age-related health concerns like kidney disease and arthritis. Diagnostic tests for parasites like intestinal worms and heartworms are essential for the health of cats. As the cat population increases, so does the demand for preventive diagnostic services.
Testing Category Outlook
By testing category, the market is categorized into clinical chemistry, microbiology, parasitology, histopathology, cytopathology, hematology, immunology & serology, imaging, molecular diagnostics, and others. In 2022, the clinical chemistry segment held the highest revenue share in the market. Clinical chemistry tests are routinely used to assess companion animals' overall health and well-being. They provide baseline data veterinarians use to monitor an animal's health over time. Clinical chemistry tests can detect the presence of various diseases and health conditions in companion animals.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, North America led the market by generating the highest revenue share. North America has one of the largest markets globally. The market continues to grow due to increasing pet ownership, rising awareness of pet health, advancements in diagnostic technologies, and a growing emphasis on preventive healthcare for pets. Veterinary clinics and hospitals across North America offer various diagnostic services, including blood tests, urinalysis, radiology, ultrasonography, and endoscopy. These facilities provide comprehensive care for companion animals. North America boasts a robust and growing market, driven by pet ownership trends, advanced healthcare practices, and a strong emphasis on pet health and well-being. This region remains at the forefront of veterinary diagnostics innovation and adoption.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zoetis, Inc., IDEXX Laboratories, Inc., Mars Inc., Fujifilm Holdings Corporation, Embark Veterinary, Inc., Thermo Fisher Scientific Inc., Patterson Companies, Inc., Randox Laboratories Limited, CVS Group Plc, and Neogen Corporation
Recent Strategies Deployed in Companion Animal Diagnostic Services Market
Partnerships, Collaborations, and Agreements:
Apr-2023: Thermo Fisher Scientific Inc. partnered with ALPCO-GeneProof, a global leader in immunodiagnostics and molecular diagnostics. Through this partnership, the TaqPath Menu | GeneProof PCR kits were introduced into the market, which strengthened the supply chains and the support systems of Thermo Fisher.
Jan-2023: Thermo Fisher Scientific Inc. formed a partnership with AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company. Under this partnership, a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib) was launched which would ease the treatment of patients with non-small cell lung cancer (NSCLC).
Oct-2022: CVS Group plc came into a partnership with Provet Cloud, an easy-to-use cloud-based veterinary practice management software. With this Partnership, CVS Group bettered its operations through Provet Cloud's large-scale implementations and open software infrastructure.
Jul-2020: Thermo Fisher Scientific Inc. signed an agreement with Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan. With this agreement, the use of the Oncomine Dx Target Test was expanded in Japan.
Product Launches and Product Expansions:
Aug-2023: Neogen Corporation Launched Igenity Enhanced Dairy, a progressive genome data management tool. Igenity Enhanced Dairy is a digital service helping dairy producers to improve their mating decisions.
Jun-2023: Neogen Corporation introduced My CatScan 2.0, facilitating genetic screening in cats. My CatScan 2.0 provides simplified experience through the utilization of a simple cheek swab method and offers data in case of over 120 genetic health conditions.
May-2023: Neogen Corporation released two assays, Reveal for Histamine and Reveal Q+ for Histamine, which help in histamine detection. Reveal and Reveal Q+ assays use water extraction method to provide results quickly, prevent disposition of chemicals and reduce the testing time.
Sep-2022: Neogen Corporation unveiled Encompass platform, for accelerating genomic results management and visualization. The Encompass platform empowers Igenity users to regulate their data and increase the benefits of genome testing.
Acquisition and Mergers:
Jun-2023: Mars, Inc. completed the acquisition of Heska Corporation, engaged in developing medical devices to improve the quality of pet care. With this acquisition, Mars would achieve wider coverage across diagnostics and technology, better R&D and access to pet healthcare solutions.
Dec-2022: Fujifilm Holdings Corporation acquired Inspirata, Inc., a leading provider of AI-NLP powered oncology informatics solutions. Through this acquisition, Fujifilm developed its Synapse Enterprise Imaging thus helping to merge pathology images and data into the electronic health record system of the healthcare organisations. Additionally, the acquisition helped to simplify care designated for oncology patients.
Sep-2022: Zoetis Inc. completed the acquisition of Jurox Pty Limited, an Australian veterinary pharmaceutical manufacturer. Through this acquisition, Zoetis achieved greater worldwide expansion and the manufacture of an anaesthetic product for companion animals called Alfaxan.
Sep-2022: Zoetis, Inc. took over NewMetrica, a developer of instruments to measure the quality of life in animals. Through this acquisition, Zoetis strengthened its capabilities and magnified expertise in quality-of-life assessments for the betterment of well-being of animals.
Jun-2022: Zoetis Inc. acquired Basepaws Inc., a petcare genetics company. Under the acquisition, Zoetis upgraded its portfolio in precision animal health and created its future roadmap towards innovations in petcare.
Jun-2021: IDEXX Laboratories, Inc. took over ezyVet, a cloud-based Practice Management software. Through this acquisition, IDEXX broadened its cloud software products that helped customers to raise the standard of care provided to the patients, improve efficiency and communications with the pet owners.
Sep-2021: Neogen Corporation took over CAPInnoVet, Inc., a fast-growing companion animal products company. Through this acquisition, Neogen paved its roadmap into the parasiticide market and improved its position within the Animal Safety business segment.
Jan-2021: Neogen Corporation acquired Megazyme, Ltd., a world leader in the development of biochemical assay kits. With this acquisition, Neogen bettered its relationship with the food producers and companies operating in the food security and quality business.
Market Segments covered in the Report:
By Type
By Animal Type
By Testing Category
By Geography
Companies Profiled
Unique Offerings from KBV Research